T-cell Therapy Market Size, Share & Analysis Report, 2024-2033

According to Nova One Advisor, the global T-cell therapy market size was valued at USD 3.85 billion in 2023 and is anticipated to reach around USD 79.62 billion by 2033, growing at a CAGR of 35.38% from 2024 to 2033.

T-cell therapy is a type of medical treatment that harnesses the power of a specific subset of immune cells called T cells to target and destroy diseased cells, particularly cancer cells. T cells are a crucial component of the immune system, responsible for recognizing and eliminating abnormal cells, including those infected by viruses or transformed into cancerous forms. T-cell therapy involves modifying or enhancing a patient’s T cells to make them more effective in targeting and eliminating specific disease-causing cells. The rising cases of cancer across the globe are observed to supplement the growth of the market. As per the statistics by IARC, it is anticipated that there are going to be approximately 28 million new cancer cases worldwide each year by 2040 if incidence remains steady and population growth and aging continue at current rates.

Get Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/7875

T-cell Therapy Market Report Highlights

• By Modality, the research-based market for T-cell therapies is expected to occupy the larger share of market space due to high number of T-cell therapy products under clinical trials.
• Commercialized T-cell therapies are expected to show significant market share in the coming years owing to the increase in the number of product approval from the regulatory body.
• By therapy type, he CAR-T therapies held the highest share of 95.66% in 2023 owing to the increase in clinical trials for CAR-T therapy products. Moreover, an increase in the usage of these therapies in different cancer is expected to boost segment growth.
• Hematological malignancies hold a major revenue share of over 55% in 2023. In order to treat lymphoma and acute lymphocytic leukaemia (ALL), the most common target of CAR T-cell therapies is CD19 on B-cells, which has led to the approval of five different CAR T therapies.

• North America held around 65.0% revenue share of the T-Cell therapy market in 2023, the regional growth is attributed to the increasing clinical trials, strong research, and increasing regulatory approval, resulting increase in the uptake of these therapies.

T-cell Therapy Market Dynamics:

Driver:

Increasing prevalence of cancer

The global burden of cancer continues to rise, with a growing number of patients diagnosed each year. T-cell therapy presents a novel approach that addresses unmet medical needs, providing an alternative for patients who have exhausted conventional treatment options. For instance, according to the National Center for Health Statistics, the United States is expected to witness 1,958,310 new cancer cases and 609,820 cancer-related deaths in 2023. Therefore, the increasing prevalence of cancer is expected to propel the T-cell therapy market during the forecast period.

Restraint:

High cost

T-cell therapy, particularly CAR T-cell therapy, can be expensive to develop, manufacture, and administer. The complex process of modifying a patient’s T cells, the need for specialized facilities, and the personalized nature of the treatment contribute to high costs. These costs can limit accessibility for patients and strain healthcare systems. For instance, according to the Journals of the American Medical Association, the cost of CAR T-cell therapy is around USD 373,000 to USD 475,000. Thus, the high cost of therapy limits patients and acts as a major restraint for the market.

Opportunity:

Increasing approvals for therapies

The increasing approvals by the Food and Drug Administration (FDA) and other agencies in the area of cancer cell therapy are expected to provide a potential opportunity for market growth over the forecast period. For instance, in May 2022, Penn Medicine developed CAR T cell therapy and won FDA’s third approval. The FDA and other agencies for approval of therapies have noticed the importance of cell therapies, especially while considering the rising number of cancer patients. Moreover, strict and firm regulatory framework for the development and trials of these therapies provided by FDA is being followed by developers and researchers. Thus, it becomes easier to approve therapies. Hence, the increasing rate of approval for therapies by FDA highlights the market’s development.

Immediate Delivery Available, Get Full Access@

https://www.novaoneadvisor.com/report/checkout/7875

The transformative potential of CAR T

Groundbreaking scientific advancements have led to three CAR T approvals for ALL and DLBCL since 2017. Approved CAR T-cell therapies are focused on treating select relapsed or refractory liquid tumors that affect less than 5 percent of cancer patients today.

The pipeline of investigative CAR T-cell therapies has rapidly expanded to more than 500 trials underway in 2019. While the earliest studies on CAR T targeted CD19, clinical programs today span a wider range of targets and tumor types. Additional CAR Ts target B-cell maturation antigen (BCMA), a common cell surface antigen in multiple myeloma as well as a number of other cell surface targets. What has carried the tide in the growing industry interest in CAR Ts has been the clinical data. For example, pediatric and young adult patients with relapsed or refractory ALL achieved overall remission rate of 90 percent at 12 months with treatment with an anti-CD19 autologous CAR T therapy.

Modality Insights

The research-based market for T-cell therapies dominated the modality segment owing to the high number of T-cell therapy products in the clinical development phase. Several research institutions, including Mayo Clinic, are actively involved in operating CAR-T therapy programs, promoting the strategy as a better way to control cancer.

The shift in focus on advancing the development of CAR-T therapies to broaden the scope of therapeutic application is the result of several operating companies working with research groups around the world. For instance, in November 2023, the Peter MacCallum Cancer Centre (Peter Mac) entered into a joint development programme agreement (CDPA) with Cartherics Pty Ltd (Cartherics) to develop Cartherics’ patented autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma. Setting up CTH-001’s clinical-scale manufacturing and carrying out a phase-I clinical trial are the core elements of the collaborative research.

On the other hand, commercialized products segment is expected to show a significant market share owing to increasing product approval from the regulatory bodies to propel the commercial use of T-cell therapies in hospital and clinical settings. For instance, in August 2023, the FDA approved Bristol Myers Squibb’s Breyanzi CAR T Cell Therapy for relapsed or refractory large B-cell lymphoma.

Therapy Type Insights

The CAR-T therapies held the highest share of 95.66% in 2023, owing to the exponential growth in the number of CAR-T therapy clinical studies and the rising engagement of major players in this market. Clinical studies for CAR-T therapy products are being conducted by a significant number of new players and academic institutions for both the same and different indications, strengthening the segment’s dominance.

The use of CAR-T therapies in the treatment of different cancers has increased as a result of improvements in their manufacturing. Emergence of new strategies like second- and next-generation CAR-T immunotherapy can overcome challenges like resistance and adverse effects, increasing the generation of organic revenue.

On the other hand, T-cell receptor-based therapies is expected to show significant growth at a CAGR of over 30% by 2033 owing to their potential for the treatment of solid malignancies. For the treatment of melanoma, this area is receiving a lot of attention. In partnership with GlaxoSmithKline, Adaptimmune is one of the company that specializes in TCR therapy for melanoma.

T-Cell Therapy Market Revenue (By Therapy Type) 2023-2033(US$ Billion)

Indication Insights

Hematological malignancies hold a major revenue share of over 55% in 2023. Since receiving initial FDA approval in 2017, CAR-T cell therapy has demonstrated promising efficacy against a number of hematological malignancies and even offer patients with severe diseases, such as B cell acute lymphoblastic leukemia or lymphoma, a curative treatment option. B cell maturation antigen for multiple myeloma and CD19 for a variety of lymphoid malignancies, including B-ALL and diffuse large B-cell lymphoma, are the two main targets for CAR-T cell treatment that are currently licensed (DLBCL). However, with several key players entering the market and high fixed costs of producing autologous cells, the segment is anticipated to experience intense market competition in the coming years.

Solid tumors is expected to exhibit a significant market growth at a CAGR of over 25% during the forecast period. A new chimeric antigen receptor (CAR) T-cell product demonstrated promising early results in solid tumor patients both as a monotherapy and in conjunction with an mRNA vaccination. It also had an acceptable safety profile. However, due to difficulties with growth, persistence, and trafficking as well as interactions with the aggressive tumor microenvironment, the therapy has limited applications for patients with solid tumors (TME).

T-Cell Therapy Market Revenue (By Indication) 2023-2033 (US$ Billion)

Regional Insights

North America held around 65.0% revenue share of the T-Cell therapy market in 2023. The U.S.'s dominance in the global market has largely been attributed to the region’s strong research, commercial base, and large number of clinical studies being done for T-cell therapies nationwide.

Additionally, the growing number of regulatory approvals in the United States and Canada as well as the changing reimbursement landscape in the region have accelerated the uptake of these therapies, creating significant market growth.

Asia Pacific region is expected to witness a rapid CAGR of over 30% during the forecast period. China holds the most registered clinical trials for CAR-T therapies, making it an attractive market for these therapies in recent years. The nation has had substantial growth as a consequence of concentrated efforts on government investment and reforms, and as a result, it has the fastest CAGR in the Asia-Pacific.

T-Cell Therapy Market Revenue, By Region (US$ Billion)

Some of the prominent players in the T-Cell therapy market include:

• Novartis AG
• Merck KGaA
• Gilead Sciences Inc.
• TCR2 Therapeutics Inc
• Bluebird Bio Inc.
• Sorrento Therapeutics
• Fate Therapeutics
• Pfizer Inc.
• Amgen
• Celgene Corporation

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global T-Cell therapy market.

Therapy Type

• CAR T-cell Therapy
• T Cell Receptor (TCR)-based
• Tumor Infiltrating Lymphocytes (TIL)-based

Indication

• Hematologic Malignancies
  • Lymphoma
  • Leukemia
  • Myeloma

• Solid Tumors
  • Melanoma
  • Brain & Central Nervous System
  • Liver Cancer
  • Others

• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Immediate Delivery Available | Buy This Premium Research

https://www.novaoneadvisor.com/report/checkout/7875

Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |Europe: +44 2080772818

Email: sales@novaoneadvisor.com